Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C20H17ClF3N5O3 and a molecular weight of 467.83 g/mol[6][1][7]. It is referenced in DrugBank as DB07550 and has been studied primarily as an experimental ligand in structural biology and drug discovery contexts[6][1]. The structure features a pyrazine core substituted with chloro, difluoropyridinyl, and fluorophenylmethyl groups. There is no evidence of clinical use or approval for any therapeutic indication. Its mechanism of action has not been characterized in public databases; it may have been explored as an inhibitor or modulator in biochemical assays but lacks published pharmacological data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(6-chloro-3-{[2,2-difluoro-2-(1-oxido-2-pyridinyl)ethyl]amino}-2-oxo-1(2h)-pyrazinyl)-n-[(2-fluorophenyl)methyl]acetamide.